![James Singleton](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
James Singleton
Direttore/Membro del Consiglio presso Tremeau Pharmaceuticals, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Bradford C. Sippy | M | - |
Tremeau Pharmaceuticals, Inc.
![]() Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | 8 anni |
Travis Helm | M | - |
Tremeau Pharmaceuticals, Inc.
![]() Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | 5 anni |
David S. Moore | M | 50 |
Tremeau Pharmaceuticals, Inc.
![]() Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | - |
Travis Wilson | M | - |
Tremeau Pharmaceuticals, Inc.
![]() Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | - |
Chris Fanale | M | - |
Tremeau Pharmaceuticals, Inc.
![]() Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 5 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- James Singleton
- Contatti personali